SCHEMBL4674947

SCHEMBL4674947

O=C(Cc1ccc(S(=O)(=O)c2ccccc2)[nH]1)C(=O)c1nc[nH]n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.36
NAMPT P43490 2/20 0.35
MMP2 P08253 5/20 0.33
MMP12 P39900 4/20 0.33
MMP13 P45452 4/20 0.33
MMP14 P50281 4/20 0.33
MMP9 P14780 3/20 0.33
MMP1 P03956 2/20 0.33
MMP3 P08254 2/20 0.33
MMP8 P22894 3/20 0.32
MMP16 P51512 3/20 0.32
F2 P00734 1/20 0.32
TBXA2R P21731 1/20 0.31
TBXAS1 P24557 1/20 0.31
GAA P10253 2/20 0.30
PRMT1 Q99873 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
POLB P06746 1/20 0.30
TUBB4A P04350 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4670860 0.90 ALDH1A1 (0.33) ALDH1A1NAMPTL3MBTL1POLB
SCHEMBL4677905 0.90 ALDH1A1 (0.33) ALDH1A1MMP2MMP12MMP13MMP14
SCHEMBL4672334 0.81 ERCC5 (0.38) ALDH1A1NAMPTPRMT1L3MBTL1
SCHEMBL4677297 0.81 ALDH1A1 (0.35) ALDH1A1NAMPTF2PRMT1L3MBTL1
SCHEMBL4675421 0.80 NAMPT (0.34) ALDH1A1NAMPTTBXA2RTBXAS1GAA
SCHEMBL4673018 0.78 NAMPT (0.34) ALDH1A1NAMPTMMP2MMP12MMP13
SCHEMBL4679269 0.78 HCAR2 (0.39) L3MBTL1
SCHEMBL4670967 0.77 MMP2 (0.37) ALDH1A1NAMPTMMP2MMP12MMP13
SCHEMBL4674547 0.76 LOX (0.49)
SCHEMBL4672436 0.76 ALDH1A1 (0.33) ALDH1A1NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 ALDH1A1 980/4885NAMPT 2333/4885MMP2 1886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.